Personalized Rituximab Treatment Based on Artificial Intelligence in Membranous Nephropathy (iRITUX)
Key facts
- Who runs it
- Centre Hospitalier Universitaire de Nice
- Where
- France15 sites in 1 countryChoose a country to see its sites
- Trial code
- Status
- Recruiting
- Phase
- Phase 3
- People taking part
- 120 people, planned
- Started
- 4 Feb 2025
- Expected to end
- 30 Sept 2031
- Type of study
- Interventional, 2 groupsOne group gets an existing treatment, for comparison.
- Treatments tested
- RiTUXimab Injection
- Record updated
- 22 June 2026
Who can take part
- Age
- 18 years and older
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 16 criteriaShow less
Who can take part
- Age ≥ 18 years
- Ongoing episode of membranous nephropathy diagnosed by the presence of anti-PLA2R1 antibodies detected by ELISA (≥ 14 RU/ml, EUROIMMUN): the result must be validated by the Coordination team before randomization
- Nephrotic syndrome defined by proteinuria > 3.5 g/24h (or UPCR > 3.5 g/g) and serum albumin < 30 g/L at diagnosis
- Estimated Glomerular Filtration Rate (CKD-EPI formula) > 30 mL/min/1,73 m2
- Indication for rituximab treatment according to the KDIGO and French guidelines
- Non-immunosuppressive antiproteinuric treatment at stable dose for 2 weeks according to French guidelines, including a renin angiotensin aldosterone system inhibitor, a diuretic and a low-salt diet at maximal tolerated dose (i.e., absence of orthostatic hypotension and no increase in creatinine > 30%)
Who cannot take part
- Presence of anti-rituximab antibodies detected by Central Lab
- Secondary Membranous nephropathy related to cancer, infection, systemic lupus, drug
- Cancer under treatment
- Patients with active, severe infections
- Hypersensitivity to the active substance or excipients
- Severe heart failure or severe, uncontrolled cardiac disease
- Diagnosis of PLA2R1-associated Membranous nephropathy not confirmed by the Coordination team (validation mandatory for randomization)
- Pregnancy or breastfeeding
- Immunosuppressive treatment (including rituximab) in the 6 months preceding inclusion
- Patients severely immunocompromised
This trial has no sites in United States.
It has sites in one country. Choose a country to see its sites.
About the trial
What the trial wants to find out
Membranous nephropathy is an autoimmune disease affecting the kidney, and the most common cause of nephrotic syndrome in non-diabetic Caucasian adults. The course of this disease is highly variable from one individual to another, ranging from spontaneous remission to progressive chronic kidney disease.
Read full original descriptionShow less
The identification of autoantibodies - e.g., the phospholipase A2 receptor type 1 (PLA2R1) - has promoted the use of immunosuppressive drugs such as rituximab which is now a safe and effective first-line treatment for the management of membranous nephropathy. However, up to 40% of patients do not respond to a first course of rituximab treatment. In nephrotic patients, due to urinary drug loss, rituximab blood level is lower than in other autoimmune diseases treated with rituximab without proteinuria. This high urinary drug loss decreases the drug exposure, potentially explaining why rituximab regimen with low dose infusions (375 mg/m2) did not demonstrate efficacy after month-6 compared to a non-immunosuppressive antiproteinuric treatment in a previous study. In contrast, a regimen of two 1-g infusions two weeks apart was associated with a significantly greater remission rate after 6 months.
Recently, the investigators have shown that after two 1-g rituximab infusions, the rituximab blood level 3 months after the first rituximab infusion, was correlated with the likelihood of remission after 6 and 12 months of the rituximab treatment. Patients with positive rituximab blood level 3 months after treatment had a higher chance of remission at month-6 and at month-12 than patients with an undetectable rituximab level at month-3.
Nowadays, machine learning algorithms are increasingly used in medicine, especially in pharmacology, to predict the exposure to a drug, the initial dose to administer or the interval between two infusions.
The objective of this study is to use a machine learning algorithm predicting the risk of having an undetectable residual level of rituximab 3 months after treatment, in order to propose a personalized treatment management with early additional doses of rituximab for the patients at risk.
The 2 groups in the trial
- Standard-of-careExisting treatment, for comparison
rituximab treatment 1gram x 2 (day-0, day-15)
Treatment: RiTUXimab Injection
- Personalised treatmentTreatment being tested
personalized treatment based on the algorithm for assessing the risk of having undetectable rituximab level after 3 months: * Patients with a risk between 0 and 50% will receive 1gram x2 (day-0, day-15) * Patients with a risk between 51 and 75% will receive 1gram x 3 (day-0, day-15, day-30) * Patients with a risk between 76 and 100% will receive 1gram x 4 (day-0, day-15, day-30, day-45)
Treatment: RiTUXimab Injection
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov and on the EU's official list of trials (CTIS).How to verify a trial in the registry
- Official title
- Study of Artificial Intelligence-based Personalized Rituximab Treatment Protocol in Membranous Nephropathy
- Publications
- Record updated
- 22 June 2026